News

Corporate Presentations • Actinogen

XanaMIA Part A Trial positive topline results for Xanamem – Webcast 27 April 2022

Actinogen announced positive topline results for its XanaMIA Part A trial involving its small molecule drug Xanamem on 27 April 2022.  Watch the recording here of the webcast and Q&A session hosted by CEO Dr Steven Gourlay and CMO Professor Paul Rolan to get a more in-depth picture about this exciting news for the company.

27 Apr 2022
04 May 2022 Actinogen Actinogen trial results & strategic update presentation
27 Apr 2022 Actinogen XanaMIA Part A Trial positive topline results for Xanamem – Webcast 27 April 2022
27 Apr 2022 Actinogen ACW positive XanaMIA results webcast slide presentation
01 Mar 2022 Actinogen Actinogen CEO presents at Sachs 15th Annual European Life Sciences Conference
10 Jan 2022 Actinogen Actinogen CEO Presents at San Francisco Healthcare Conference
25 Nov 2021 Actinogen Actinogen Webcast of Strategic Update and Capital Raising Investor Presentation
25 Nov 2021 Actinogen Actinogen Strategic Update & Capital Raising Investor Presentation
10 Nov 2021 Actinogen Actinogen Annual General Meeting 10 Nov 2021: Webcast presentation
10 Nov 2021 Actinogen Actinogen Annual General Meeting 10 Nov 2021: AGM Presentations
10 Jun 2021 Actinogen BIO Digital 2021: Company presentation (10-11 & 14-18 June 2021)
30 Apr 2021 Actinogen Strategic Update Teleconference Transcript
21 Apr 2021 Actinogen Actinogen Strategic Update and Investor Presentation
27 Nov 2020 Open Briefing Actinogen Annual General Meeting 27 Nov 2020: Webcast presentation
27 Nov 2020 Actinogen Actinogen Annual General Meeting 27 Nov 2020: Audio only
27 Nov 2020 Actinogen Actinogen Annual General Meeting 27 Nov 2020: AGM Presentations
02 Nov 2020 Actinogen Actinogen presentation: New clinical development opportunity Fragile X syndrome (Nov 2020)
28 Oct 2020 Actinogen Monsoon Morning Twilight Investor Briefing (28 Oct 2020) Actinogen presentation
19 Oct 2020 Actinogen Actinogen Conference Call 19 Oct 2020: Webcast presentation
08 Sep 2020 ASX ASX Small & Mid-Cap Conference (8-10 Sep 2020): Actinogen pre-recorded presentation with Dr Bill Ketelbey
08 Sep 2020 Actinogen ASX Small & Mid-Cap Conference (8-10 Sep 2020): Actinogen investor presentation
31 Jul 2020 Actinogen Alzheimer’s Association International Conference (AAIC) Virtual Event (27-31 Jul 2020) Poster presentation by Prof Craig Ritchie, Chair of Actinogen Xanamem Clinical Advisory Board on behalf of Actinogen “Drug Development Summary for Xanamem™, a Potent Inhibitor of the 11β-HSD1 Enzyme”
31 Jul 2020 Finance News Network FNN CEO Showcase: Actinogen (ASX:ACW) Presentation, FNN Online Investor Event, July 2020
15 Jul 2020 Actinogen Bio Digital 2020: Company presentation and audio
08 Jun 2020 Actinogen Bio Digital 2020: Company presentation
08 Jun 2020 Actinogen BIO Digital 2020: Company presentation for partnering meetings
29 Apr 2020 Actinogen AAT/AD-PD 2020: Actinogen Full Presentation with Audio presented by Professor Craig Ritchie, Chair of Actinogen’s Xanamem Clinical Advisory Board. Chronically elevated cortisol and cognitive impairment: The therapeutic potential of Xanamem, a potent inhibitor of the 11β-HSD1 enzyme
29 Apr 2020 Actinogen AAT-AD/PD 2020: Actinogen Presentation Summary
29 Apr 2020 Actinogen AAT-AD/PD 2020: Actinogen Presentation Only Excluding Audio
29 Jan 2020 Sachs TV 3rd Annual SACHS Neuroscience Innovation Forum: Dr Bill Ketelbey, CEO Actinogen presentation in San Francisco, USA
25 Nov 2019 Actinogen AGM 2019: Managing Directors Address to Shareholders
25 Nov 2019 Actinogen AGM 2019: Managing Director’s Presentation
06 Nov 2019 Small Caps Australian Microcap Investment Conference 2019: Actinogen presentation
25 Sep 2019 Actinogen AAIC Satellite Symposium: Poster Presentation. Chronically Elevated Cortisol and Cognitive Impairment: The Therapeutic Potential of Xanamem™, a Potent Inhibitor of the 11β-HSD1 Enzyme
26 Jun 2019 Actinogen Investor Presentation Jun 2019: A novel approach to treating cognitive impairment and Alzheimer’s disease
07 Jan 2019 Actinogen ACW Presents at SACHS Neuroscience Forum during JPM Week
06 Jan 2019 Sachs TV 2nd Annual SACHS Neuroscience Innovation Forum: Dr Bill Ketelbey presentation in San Francisco, USA
28 Nov 2018 Actinogen AGM: Managing Director’s Presentation 2018
26 Nov 2018 Actinogen Investor Presentation Nov 2018: A novel approach to treating cognitive impairment and Alzheimer’s disease
30 Oct 2018 Actinogen Australia Biotech Invest & Partnering 2018: Oct 2018
17 Oct 2018 Actinogen Australian Microcap Investment Conference Oct 2018: A novel approach to treating cognitive impairment and Alzheimer’s disease
25 Sep 2018 FNN Investor Event Actinogen (ASX:ACW) Phase II Alzheimer’s trials
12 Sep 2018 Actinogen Singapore Healthcare Investor Day Sep 2018: Alzheimer’s Treatment Needs a New Approach – Xanamem
04 Jun 2018 Actinogen BIO International Convention Jun 2018: Presentation ‘Alzheimer’s Treatment Needs a New Approach – Xanamem’
30 May 2018 Open Briefing Investor Conference Call Transcript: 30 May 2018
30 May 2018 Actinogen Investor Conference Call Audio: 30 May 2018
28 May 2018 Actinogen Investor Presentation: May/Jun 2018
05 Apr 2018 Actinogen Investor Open Briefing March 2018
29 Nov 2017 Actinogen AGM: Managing Director’s Presentation 2017
16 Oct 2017 Actinogen Investor Presentation: Oct 2017
27 Mar 2017 Actinogen Investor Presentation: March 2017

Back
to top